# Technology Summary for Diligence

> Confidentiality: Level 3 — NDA controlled unless otherwise stated.
> Boundary: preclinical R&D due-diligence materials; not clinical validation or human-use authorization.


## What the repository demonstrates
- Modular C++17 architecture with runtime, safety, neural-chip, full-dive scaffolding, HIL, hardware-bench, replay, security, QMS, readiness, and performance areas.
- Traceable QMS documentation and checks suitable for expert review.
- Safety-gate oriented design, including explicit non-human-use posture and signed-evidence gate concepts.
- Due-diligence packaging for NDA-controlled disclosure, source integrity, build/test reproduction, IP/provenance review, and supply-chain review.

## Defensible value basis
| Value driver | Diligence evidence | Boundary |
| --- | --- | --- |
| Architecture | Source tree, technical docs, traceability | Requires independent architecture review |
| Implementation depth | Source manifest and repository inventory | File counts are not clinical proof |
| QMS readiness | Required-doc and traceability checks | Internal readiness only |
| Test base | CMake/CTest configuration and evidence reports | Full logs must be attached per release |
| Safety posture | Human-use locks and clinical claim guards | Does not authorize human deployment |
| Integration potential | Feasibility matrix and transition plan | Target-specific adapter work remains |

## Non-overpromise statement
This package supports acquisition diligence and technical review. It must not be represented as a clinically validated, certified, approved, implant-ready, or human-use-ready product.
